145 248

Cited 0 times in

Effects of a Mixture of Ivy Leaf Extract and Coptidis rhizome on Patients with Chronic Bronchitis and Bronchiectasis

Authors
 Goohyeon Hong  ;  Yu-Il Kim  ;  Seoung Ju Park  ;  Sung Yong Lee  ;  Jin Woo Kim  ;  Seong Hoon Yoon  ;  Keu Sung Lee  ;  Min Kwang Byun  ;  Hak-Ryul Kim  ;  Jaeho Chung 
Citation
 INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, Vol.18(8) : 4024, 2021-04 
Journal Title
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
ISSN
 1661-7827 
Issue Date
2021-04
MeSH
Adult ; Aged ; Aged, 80 and over ; Bronchiectasis* / drug therapy ; Bronchitis, Chronic* / drug therapy ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Plant Extracts / therapeutic use ; Prospective Studies ; Quality of Life ; Rhizome
Keywords
berberine ; bronchiectasis ; chronic bronchitis ; hederacoside C ; mucolytic agent
Abstract
Background: Hederacoside C from ivy leaf dry extracts (HH) and berberine from Coptidis rhizome dry extracts (CR) can be combined (HHCR) as a herbal product. Previous studies have demonstrated that HHCR has antitussive and expectorant effects in animal models of respiratory disease. However, the therapeutic effects of HHCR on respiratory diseases in humans have not been well-studied. Therefore, we aimed to clarify the effectiveness of HHCR in patients with chronic bronchitis and bronchiectasis.

Methods: This was a multicenter (10 university teaching hospitals), open-label, prospective, single-arm, observational study. Consecutive patients with chronic bronchitis and bronchiectasis were included. Patients were orally treated with HHCR daily for 12 weeks. St. George's Respiratory Questionnaire (SGRQ) scores and bronchitis severity scores (BSS) were measured at baseline and at the end of the 12-week study.

Results: In total, 376 patients were enrolled, of which 304 were finally included in the study, including 236 males and 68 females with a median age of 69 years (range: 37-88 years). After 12 weeks of HHCR treatment, there was a significant improvement in SGRQ score (baseline, 32.52 ± 16.93 vs. end of study, 29.08 ± 15.16; p < 0.0001) and a significant reduction in BSS (baseline, 7.16 ± 2.63 vs. end of study, 4.72 ± 2.45; p < 0.0001). During the study, 14 patients concomitantly used an inhaled corticosteroid and 83 patients used an inhaled bronchodilator. HHCR also had significant positive effects on these patients in terms of SGRQ score and BSS. No serious adverse drug reactions occurred during HHCR treatment.

Conclusions: treatment with HHCR improved the SGRQ score and BSS in patients with chronic bronchitis and bronchiectasis. HHCR may be a new therapeutic option for chronic bronchitis and bronchiectasis. Large-scale, randomized, double-blind, placebo-controlled clinical trials are warranted.
Files in This Item:
T202104925.pdf Download
DOI
10.3390/ijerph18084024
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Byun, Min Kwang(변민광) ORCID logo https://orcid.org/0000-0003-1525-1745
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/187006
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links